Headquartered in Eagan, MN·Fiscal year ends December·NYSE: SOLV·solventum.com
About Solventum
Solventum Corporation is a healthcare technology company spun off from 3M in 2024 that operates at the intersection of health, material, and data science. The company is organized into three reportable segments: MedSurg (which encompasses Advanced Wound Care products such as negative pressure wound therapy and advanced dressings, and Infection Prevention and Surgical Solutions including IV site management, sterilization assurance, surgical supplies, and medical electrodes), Dental Solutions (dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents), and Health Information Systems (software solutions for healthcare revenue cycle management including computer-assisted physician documentation, coding automation, speech recognition, and data visualization). The company sold its Purification and Filtration business in September 2025 and has announced its intent to separate the Health Information Systems segment to sharpen its focus as a dedicated MedTech company. Solventum acquired Acera Surgical in December 2025 to bolster its wound care portfolio. The company serves healthcare professionals and systems globally with products designed to improve clinical outcomes and operational efficiency. Updated
Nelson Peltz just made a healthcare technology spinoff his largest institutional bet, and the combination of a dirt-cheap valuation, an activist legend, and a company still sorting out its own identity creates…
Solventum Corporation is a healthcare technology company spun off from 3M in 2024 that operates at the intersection of health, material, and data science.
What is the SOLV stock price target?
24/7 Wall St.'s 12-month price target for SOLV is $108.92, rated Buy. The Wall Street consensus target is $94.31. SOLV price prediction →